Fatima Laher to Immunogenicity, Vaccine
This is a "connection" page, showing publications Fatima Laher has written about Immunogenicity, Vaccine.
Connection Strength
0,401
-
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021 03 25; 384(12):1089-1100.
Score: 0,180
-
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
Score: 0,167
-
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Med. 2024 Mar; 21(3):e1004360.
Score: 0,055